After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.
Trade-Ideas LLC identified Coherus BioSciences (CHRS) as a weak on high relative volume candidate
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.